QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=C057DE3D41D9400A19D1CA708AC75D4C;jsessionid=8024CB861F67EABF3542FC05E9ADF376;jsessionid=0A1099CEF2F866A9749C5B940E7651E2;jsessionid=CDAE8FAB44CF38DD8FF1D6B4F3BA5973;jsessionid=2DE812E1DB6080E2DB2B268E41A4CD11;jsessionid=3AA6CB1B93F1FB93161B78A8A4E3140F;jsessionid=37532F632DE75A82388AB23478E8894D;jsessionid=474D599F317E8CDAB75993EE19E064EE;jsessionid=0C68E75970A04CE6F2B552D600171133 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=C057DE3D41D9400A19D1CA708AC75D4C;jsessionid=8024CB861F67EABF3542FC05E9ADF376;jsessionid=0A1099CEF2F866A9749C5B940E7651E2;jsessionid=CDAE8FAB44CF38DD8FF1D6B4F3BA5973;jsessionid=2DE812E1DB6080E2DB2B268E41A4CD11;jsessionid=3AA6CB1B93F1FB93161B78A8A4E3140F;jsessionid=37532F632DE75A82388AB23478E8894D;jsessionid=474D599F317E8CDAB75993EE19E064EE;jsessionid=0C68E75970A04CE6F2B552D600171133